5 Healthcare Stocks to Invest In Today According to Stanley Druckenmiller

3. Reata Pharmaceuticals, Inc. (NASDAQ:RETA)

Duquesne Family Office’s Stake Value: $10.7 million

Percentage of Duquesne Family Office’s 13F Portfolio: 0.38%

Number of Hedge Fund Holders: 13

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) is a biopharmaceutical firm that develops treatments for patients with life threatening diseases. These include neurological, kidney, and other diseases.

As the fourth quarter of last year came to an end, Duquesne Family Office had owned 406,264 Reata Pharmaceuticals, Inc. (NASDAQ:RETA) shares which were worth $10.7 million and represented 0.38% of its investment portfolio. Insider Monkey’s 924 hedge fund survey during the same time period revealed that 13 had also owned the company’s shares.

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) reported $0.93 million in revenue and -$1.59 in non-GAAP EPS, in a huge miss that saw the company fall short of Wall Street revenue estimates by $830,000. Goldman Sachs set a $91 price target for the company in March 2022, stating that it has confidence in a drug following positive data.

Reata Pharmaceuticals, Inc. (NASDAQ:RETA)’s largest shareholder is Israel Englander’s Millennium Management which owns 608,951 shares that are worth $16 million.